



#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Franklin, et al.  
Serial No.: 09/938,269 Art Unit: 1614  
Filing Date: August 23, 2001 Examiner:  
For: Treatment of Trauma  
Docket No. 314572-105

Commissioner for Patents  
Washington, DC 20231

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on March 5, 2002

By: Sally B. Hansen  
Sally B. Hansen

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.56

Applicants herein make available to the Patent and Trademark Office copies of the documents:

- ☒ listed on enclosed Form PTO/SB/08A/B (Formerly PTO-1449), in accordance with 37 CFR 1.98(a)(2); and
- ☒ listed on enclosed copies of Forms PTO-1449, PTO-892 or PTO/SB/08A/B, which forms recited the application information for applications to which this application claims priority under 35 U.S.C. §120. Pursuant to 37 CFR 1.98(d), NO COPIES OF THESE DOCUMENTS ARE ENCLOSED. The prior applications that provide the source of these documents are:

Serial No. 09/644,121, filed August 23, 2000;

Serial No. \_\_\_\_\_, filed \_\_\_\_\_;

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of this application. It is believed that the Examiner will concur with Applicant's belief that the foregoing references do not adversely affect the patentability of the subject matter presently claimed, taken alone or in combination.

It is requested that the listed references be included in the "References Cited" portion of any patent issuing from this application.

(1) **This Information Disclosure Statement is being filed:**

- ☐ within three months of the filing date of the patent application.
- ☐ within three months of the date of entry into the national stage as set forth in 37 CFR 1.491 of the international application.
- ☒ **before** the mailing date of a first Office Action on the merits.
- ☐ **after** the mailing date of the first Office Action on the merits, but **before** the mailing date of
  - a Final Action under 37 CFR 1.113,
  - a Notice of Allowance under 37 CFR 1.311, or
  - an action that otherwise closes prosecution,and is accompanied by either:
  - ☐ the Statement under 37 CFR 1.97(e) (see "Statement" below), **or**
  - ☐ the fee under 37 CFR 1.17(p).
- ☐ **after** the mailing date of
  - a Final Action under 37 CFR 1.113,
  - a Notice of Allowance under 37 CFR 1.311, or
  - an action that otherwise closes prosecution,,and is accompanied by both:
  - the Statement under 37 CFR 1.97(e) (see "Statement" below), **and**
  - the fee under 37 CFR 1.17(p).

(2) **Statement**

- ☐ The **undersigned attorney** hereby states that each item information contained in the Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Supplemental Information Disclosure Statement. *(If this box is checked, do not check any further Statement boxes.)*
- or**
- ☐ The **person signing immediately below** hereby states that no item of information contained in the Supplemental Information Disclosure was

cited in any communication from any foreign patent office in any counterpart foreign patent application or, to the knowledge of the person signing after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Supplemental Information Disclosure Statement.

*The person making the statement is:*

☐ the inventor(s) who sign(s) below:

\_\_\_\_\_  
*Signature of the Inventor(s)*

\_\_\_\_\_  
*Typed or Printed Name of the Inventor(s)*

**or**

☐ a person who is substantively involved in the preparation or prosecution of the application, and who is associated with the inventor(s), or with the assignee, or with anyone to whom there is an obligation to assign the application (37 CFR 1.565(c)) and who signs below:

\_\_\_\_\_  
*Signature of the Person(s)*

\_\_\_\_\_  
*Typed or Printed Name of the Person*

\_\_\_\_\_  
*Address of Person Signing*

**or**

☐ the undersigned attorney who signs on the basis of the information:

☐ supplied by the inventor(s).

☐ supplied by an individual designated in 37 CFR 1.56(c).

☐ in the attorney's file.

\_\_\_\_\_  
*Signature of the Attorney (4) Fees*

☒ **No Fee** is owed by the applicants.

☐ The IDS Fee of \$180.00 under 37 CFR 1.17(p) is enclosed herewith.

(5) **Method of Payment of Fees**


- ☐ Attached is a check in the amount of \$\_\_\_\_\_.
- ☐ Applicants hereby authorize the Commissioner to charge the \$180.00 IDS Fee to Deposit Account No. 04-0480.

(6) **Authorization to Charge Additional Fees**

- ☒ Applicants hereby authorize the Commissioner to charge any additional fees deemed required for consideration of this Paper to Deposit Account No. 04-0480.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,



Arthur E. Jackson  
Registration No. 34,354

DECHERT  
P.O. Box 5218  
Princeton, NJ 08543-5218  
Fax: (609)620-3259  
Attn: Arthur E. Jackson, Esq.  
(609)620-3254





Form PTO - 1449 U.S. Department of Commerce  
(Modified) Patent and Trademark Office

Attorney Docket No. 314572-103 C  
Serial No.: 09/644,121  
Applicant: Hubbell et al.  
Filing Date: August 23, 2000  
Group No. Not Yet Assigned

**Information Disclosure  
Statement by Applicant**  
(use several Sheets if necessary)

**U.S. PATENT DOCUMENTS**

Exmr Initial	Patent Number	Issue Date	Patentee	Class	Sub- Class	Filing Date If Appropriate
AA	5,939,208	8/17/99	Stoy			
BB	5,423,736	6/13/95	Cartmell et al.			
CC	5,306,504	4/26/94	Lorenz			
DD	5,204,110	4/20/93	Cartmell et al.			
EE	5,160,328	11/3/92	Cartmell et al.			
FF	5,154,706	10/13/92	Cartmell et al.			
GG	5,920,158	7/6/99	Miller et al.			
HH	5,705,177	1/6/98	Roufa et al.			
II	5,705,178	1/6/98	Roufa et al.			
JJ	5,080,893	1/14/92	Goldberg et al.			
KK	6,010,692	1/4/00	Goldberg et al.			
LL	5,885,566	3/23/99	Goldberg			
MM	5,665,477	9/9/97	Meathrel et al.			
NN	5,350,573	9/27/94	Goldberg et al.			
OO	5,140,016	8/18/92	Goldberg et al.			

**FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION**

Exmr Initial	Document Number	Publn Date*	Country or Patent Office	Class	Sub- Class	Translation? Yes No
PP	EP 0952171A2	10/27/99	Europe			
QQ	WO 97/05185	2/13/97	PCT			
RR	WO 99/44557	9/10/99	PCT			
SS	WO 99/47129	9/23/99	PCT			
TT	WO 95/15352	6/8/95	PCT			
UU	EP 0604101A1	12/14/93	Europe			
VV	WO 92/06748	4/30/92	PCT			
WW	EP 0426422A2	10/30/90	Europe			
XX	EP 0068509B1	8/25/85	Europe			
YY	WO 00/44808	8/3/00	PCT			
ZZ	JP262249	10/7/97	Japan			No

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Place of Publication\*\*)**

AB	Fate of Water-Soluble Polymers Administered via Different Routes, Tetsuji et al.; J of Pharm. Sci Vol. 84, No. 3, March 1995 Pg. 349-354.
Examiner	Date Considered

**EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

---

(Form PTO - 2)

- \* Use publication date indicated on the patent or published application. 37 CFR 1.98(b).
- \*\* The place or publication refers to the name of the journal, magazine or other publication in which the article was published. Notice of January 9, 1992, 1135 O.G. 13 to 25 at 20.

96298.1.07